Gustav Sten - AroCell AB Chief Officer
AROC Stock | SEK 0.59 0.02 3.28% |
Insider
Gustav Sten is Chief Officer of AroCell AB
Phone | 46 18 50 30 20 |
Web | https://www.arocell.com |
AroCell AB Management Efficiency
The company has return on total asset (ROA) of (0.1585) % which means that it has lost $0.1585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2635) %, meaning that it generated substantial loss on money invested by shareholders. AroCell AB's management efficiency ratios could be used to measure how well AroCell AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Gabi Zijderveld | Smart Eye AB | N/A | |
Niclas Brynne | Kancera AB | 62 | |
Anders Lyrheden | Smart Eye AB | 58 | |
BA BA | Genovis AB | N/A | |
Torbjrn Lundstrm | Kancera AB | 70 | |
Martin Rydberg | Smart Eye AB | 47 | |
Rikke Rytter | Genovis AB | 56 | |
Maria Edholm | Genovis AB | N/A | |
Henrik Lind | Smart Eye AB | 62 | |
Linda Andersson | Genovis AB | 47 | |
Timothy Peacock | Smart Eye AB | N/A | |
Thomas Olin | Kancera AB | 65 | |
Peter Selin | Kancera AB | 50 | |
Fredrik Olsson | Genovis AB | 52 | |
Martin Norin | Kancera AB | 64 | |
Susanne Ahlberg | Genovis AB | 66 | |
Rana Kaliouby | Smart Eye AB | 45 | |
Magnus Langberg | Genovis AB | 52 | |
Graham Page | Smart Eye AB | N/A | |
Hans Richter | Kancera AB | 74 | |
Martin Bjuve | Smart Eye AB | N/A |
Management Performance
Return On Equity | -0.26 | |||
Return On Asset | -0.16 |
AroCell AB Leadership Team
Elected by the shareholders, the AroCell AB's board of directors comprises two types of representatives: AroCell AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AroCell. The board's role is to monitor AroCell AB's management team and ensure that shareholders' interests are well served. AroCell AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AroCell AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Gustav Sten, Chief Officer | ||
BSc BSc, Chief Officer | ||
Tina Yang, Chief Officer | ||
Marie Torstensson, Chief Officer | ||
Gunnar Wahlberg, Chief Rapid | ||
Maria Olofsson, Chief Officer | ||
Ellen Dittberner, Chief Officer | ||
Jonas Sderholm, Global Lead |
AroCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AroCell AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.26 | |||
Return On Asset | -0.16 | |||
Profit Margin | (2.04) % | |||
Operating Margin | (2.07) % | |||
Current Valuation | 63.02 M | |||
Shares Outstanding | 230.36 M | |||
Shares Owned By Insiders | 41.61 % | |||
Price To Earning | (11.21) X | |||
Price To Book | 0.55 X | |||
Price To Sales | 4.05 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AroCell Stock Analysis
When running AroCell AB's price analysis, check to measure AroCell AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AroCell AB is operating at the current time. Most of AroCell AB's value examination focuses on studying past and present price action to predict the probability of AroCell AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AroCell AB's price. Additionally, you may evaluate how the addition of AroCell AB to your portfolios can decrease your overall portfolio volatility.